Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-05-27
1996-05-14
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514410, 540543, 540545, 548416, A61K 3155
Patent
active
055167713
ABSTRACT:
The invention features a method of treating a pathological condition of the prostate gland, e.g., benign prostatic hypertrophy or prostate cancer, in a mammal, said method comprising administering to said mammal a therapeutic amount of the indolocarbazole compound K-252a or a preferred derivative thereof. The invention also includes novel derivatives of K-252a.
REFERENCES:
patent: 4877776 (1989-10-01), Murakata et al.
patent: 4923986 (1990-05-01), Murakata et al.
patent: 5043335 (1991-08-01), Kleinschroth et al.
patent: 5073633 (1991-12-01), Schroeder et al.
Akinaga et al., "Antitumor Effect of KT6124, A Novel Derivative of Protein Kinase Inhibitor K-252A, and Its Mechanism of Action", Cancer Chemother. Pharmacol. 29:266-272 (1992).
Berg et al., "K-252a Inhibits Nerve Growth Factor-Induced trk Photo-Oncogene Tyrosine Phosphorylation and Kinase Activity", J. Biological Chem. 267:13-16 (1992).
Brocker et al., "Nerve Growth and Expression of Receptors for Nerve Growth Factor in Tumors of Melanocyte Origin", J. Investigative Dermatology 96:662-665 (1991).
Cunha et al., "Normal and Abnormal Development of the Male Urogenital Tract", J. Andrology, 13:465-475 (1992).
Djakiew et al., "Regulation of Growth by a Nerve Growth Factor-Like Protein Which Modules Paracrine Interactions Between a Neoplastic Epithelial Cell Line . . . , " Cancer Research 51:3304-3310 (1991).
Elliott et al., "K252a is a Potent and Selective Inhibitor of Phosphorylase Kinase", Biochemical and Biophysical Research Communications 171:148-154 (1990).
Hashimoto et al., "Blockage of Nerve Growth Factor Action in PC12h Cells by Staurosporine, A Potent Protein Kinase Inhibitor", J. Neurochemistry 53:1675-1685 (1989).
Hempstead et al., "Overexpression of the trk Tyrosine Kinase Rapidly Accelerates Nerve Growth Factor-Induced Differentiation", Neuron 9:883-896 (1992).
Mac Morgan et al., "Expression of Nerve Growth Factor and Nerve Growth Factor Receptor Genes in Human Tissues and in Prostatic Adenocarcinoma Cell Lines", J. Neurochemistry, 59:1381-1390 (1992).
Nakagawa et al., "Association Between High Levels of Expression of the trk Gene and Favorable Outcome in Human Neuroblastoma", New England J. Medicine 328:847-854 (1993).
Nye et al., "K-252a and Staurosporine Selectively Block Autophosphorylation of Neurotrophin Receptors and Neurotrophin-Mediated Responses", Molecular Biology of the Cell 3:677-686 (1992).
Tapley et al., "K252a is a Selective Inhibitor of the Tyrosine Protein Kinase Activity of the trk Family of Oncogenes and Neurotrophin Receptors", Oncogene 7:371-381 (1992).
Morton et al., "Differential Effects of Growth Factor Antagonists on Neoplastic and Normal Prostatic Cells", The Prostate 17:327-336 (1990).
Ichikawa et al., "The Antitumor Effects of Quinoline-3-Carboxamide Linomide on Dunning R-3327 Rat Prostatic Cancers", Cancer Research 52:3022-3028 (1992).
Issacs et al., "Establishment and Characterization of Seven Dunning Rat Prostatic Cancer Cell Lines and Their Use in Developing Methods for Predicting . . . ", The Prostate 9:261-281 (1986).
Eisenberger et al., "Suramin, An Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial", J. of Nat. Cancer Institute 85:611-621 (1993).
Bozyczko-Coyne et al., "A Rapid Fluorometric Assay to Measure Neuronal Survival in Vitro", Journal of Neuroscience Methods, 50:205-216 (1993).
Hughes et al., "Synthesis of the Indolo[2,3-A]Carbazole Natural Products Staurosporinone and Arcyiaflavin B", J. Chem. Soc. Perkin Trans. 1:2475-2480 (1990).
Hirata et al., Chemical Abstracts, vol. 111, No. 21, Issued Nov. 20, 1989, Abstract 194456g.
Tishler et al., Chemical Abstracts, vol. 113, No. 21, Issued Nov. 19, 1990.
Contreras Patricia C.
Dionne Craig A.
Murakata Chikara
Burgoon, Jr. Richard P.
Cephalon Inc.
Kyowa Hakko Kogyo Co. Ltd.
Raymond Richard L.
LandOfFree
Use of indolocarbazole derivatives to treat a pathological condi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of indolocarbazole derivatives to treat a pathological condi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of indolocarbazole derivatives to treat a pathological condi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1895839